Press release
Drugs For Benign Prostatic Hypertrophy Market Report 2024 - Market Growth And Trends
"The Business Research Company recently released a comprehensive report on the Global Drugs For Benign Prostatic hypertrophy Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=2594&type=smp
According to The Business Research Company's, The drugs for benign prostatic hypertrophy market size has grown strongly in recent years. It will grow from $4.02 billion in 2023 to $4.31 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to aging population, increased awareness, advancements in drug therapies, healthcare access.
The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.45 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to emerging markets, new drug developments, increasing awareness and education, regulatory approvals. Major trends in the forecast period include minimally invasive treatments, personalized medicine, combination therapies, patient-centered care, telemedicine and digital health, research and development.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report
Market Drivers and Trends:
The rising male geriatric population globally is driving the growth of drugs for benign prostatic hypertrophy market for Benign Prostatic Hypertrophy drugs as the condition is commonly seen in men aged over 50 years. For instance, in October 2022, according to the World Health Organization, a US-based specialized health agency, globally, 1 in 6 individuals would be 60 or older by 2030 and is expected to reach 2.1 billion elderly people by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years.
Combination drugs are increasingly being used in the treatment of Benign Prostatic Hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects, and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of Benign Prostatic Hypertrophy.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Major Key Players of the Market:
Allergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, Æterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International plc, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.
Drugs For Benign Prostatic hypertrophy Market 2024 Key Insights:
• The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.45 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%.
• Rising Geriatric Population Drives Growth Of Benign Prostatic Hypertrophy Drugs Market
• Rising Adoption Of Combination Drugs Enhances Benign Prostatic Hypertrophy Treatment
• North America was the largest region in the drugs for benign prostatic hypertrophy market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=2594&type=smp
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Drugs For Benign Prostatic Hypertrophy Market Report 2024 - Market Growth And Trends here
News-ID: 3724551 • Views: …
More Releases from The Business research company
Rail Transit Protective Coating Market Overview: Major Segments, Strategic Devel …
The rail transit protective coating sector is positioned for significant expansion in the coming years, driven by technological advancements and increasing infrastructure investments. This market is evolving rapidly as stakeholders prioritize durability, sustainability, and efficiency in rail transit systems. Let's explore the market's valuation projections, leading companies, emerging trends, and detailed segment analysis to get a clearer understanding of its future trajectory.
Expected Market Size and Growth Outlook for Rail Transit…
Analysis of Segments and Major Growth Areas in the Product Implementation Servic …
The product implementation services sector is on the verge of significant expansion, driven by evolving technology needs and increasing enterprise adoption of sophisticated systems. Understanding the current market size, key contributors, emerging trends, and segment breakdowns offers valuable insights into what lies ahead for this dynamic industry.
Market Size and Expected Growth Trajectory in the Product Implementation Services Market
The product implementation services market is projected to experience strong growth…
Key Strategic Developments and Emerging Changes Shaping the Polyvinylidene Fluor …
The polyvinylidene fluoride (PVDF) resin market is on track for significant expansion over the coming years. Driven by various technological advances and rising demands across multiple industries, this sector is expected to evolve rapidly. Let's explore the anticipated market growth, influential players, key trends, and detailed segmentation shaping the future of PVDF resin.
Projected Growth and Market Size of the Polyvinylidene Fluoride Resin Market
The PVDF resin market is forecasted…
Leading Companies Fueling Innovation and Growth in the Partyline Intercom System …
The partyline intercom systems market is gearing up for significant expansion as communication needs evolve across various industries. With increasing demand for more versatile and efficient communication tools, this sector is set to witness rapid advancements and growing adoption over the coming years. Let's explore the market size projections, key drivers, major players, emerging trends, and important segments shaping this dynamic industry.
Projected Market Size and Growth Trajectory of the Partyline…
More Releases for Benign
Rising Geriatric Population Drives Growth Of Benign Prostatic Hypertrophy Drugs …
The Drugs For Benign Prostatic hypertrophy Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Drugs For Benign Prostatic hypertrophy Market?
The drugs for benign prostatic hypertrophy market has shown strong growth, expanding from $4.28 billion in 2024 to $4.58…
Prominent Drugs For Benign Prostatic hypertrophy Market Trend for 2025: Innovati …
What Are the Projected Growth and Market Size Trends for the Drugs For Benign Prostatic hypertrophy Market?
The market size for benign prostatic hypertrophy medication has seen considerable growth in recent years. It is projected to increase from $4.28 billion in 2024 to $4.58 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The significant growth during the historic period can be linked to an aging population, heightened…
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.…
Prominent Drugs For Benign Prostatic hypertrophy Market Trend for 2025: Innovati …
What Are the Projected Growth and Market Size Trends for the Drugs For Benign Prostatic hypertrophy Market?
The market size for benign prostatic hypertrophy medication has seen considerable growth in recent years. It is projected to increase from $4.28 billion in 2024 to $4.58 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The significant growth during the historic period can be linked to an aging population, heightened…
Prominent Drugs For Benign Prostatic hypertrophy Market Trend for 2025: Innovati …
What Are the Projected Growth and Market Size Trends for the Drugs For Benign Prostatic hypertrophy Market?
The market size for benign prostatic hypertrophy medication has seen considerable growth in recent years. It is projected to increase from $4.28 billion in 2024 to $4.58 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The significant growth during the historic period can be linked to an aging population, heightened…
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.…
